All Stories

  1. Aluminum in beverages and foods: A comprehensive compilation of regulations; concentrations in raw, prepared, and stored beverages and foods; and intake
  2. Dietary burden of phosphorus and aluminum concentrations of ready-to-eat wheat flour tortillas exceed that of corn tortillas: Implications for patients with renal or cardiovascular disease
  3. Macrophage Polarization Status Impacts Nanoceria Cellular Distribution but Not Its Biotransformation or Ferritin Effects
  4. Carboxylic acids and light interact to affect nanoceria stability and dissolution in acidic aqueous environments
  5. Cerium dioxide, a Jekyll and Hyde nanomaterial, can increase basal and decrease elevated inflammation and oxidative stress
  6. Laser irradiation as a novel alternative to detach intact particulate matter collected on air filters
  7. Direct nose to the brain nanomedicine delivery presents a formidable challenge
  8. The preparation temperature influences the physicochemical nature and activity of nanoceria
  9. Correction to Some Statements about Aluminum in Sulaiman et al.
  10. Nanoceria distribution and effects are mouse-strain dependent
  11. Tissue Specific Fate of Nanomaterials by Advanced Analytical Imaging Techniques - A Review
  12. Nanoparticle brain delivery: a guide to verification methods
  13. Carboxylic acids accelerate acidic environment-mediated nanoceria dissolution
  14. Surface-controlled dissolution rates: a case study of nanoceria in carboxylic acid solutions
  15. Methods to Quantify Nanomaterial Association with, and Distribution Across, the Blood–Brain Barrier In Vivo
  16. Morphometric characteristics and time to hatch as efficacious indicators for potential nanotoxicity assay in zebrafish
  17. Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics
  18. Challenges in characterizing the environmental fate and effects of carbon nanotubes and inorganic nanomaterials in aquatic systems
  19. Analytical High-resolution Electron Microscopy Reveals Organ-specific Nanoceria Bioprocessing
  20. Toxic and Essential Trace Element Content of Commonly Administered Pediatric Oral Medications
  21. Biokinetics of nanomaterials: The role of biopersistence
  22. Aluminum and Phthalates in Calcium Gluconate
  23. Aluminum☆
  24. From Dose to Response: In Vivo Nanoparticle Processing and Potential Toxicity
  25. Physicochemical properties of engineered nanomaterials that influence their nervous system distribution and effects
  26. Aluminum: The Toxicology of
  27. Silver nanoparticles induce tight junction disruption and astrocyte neurotoxicity in a rat blood–brain barrier primary triple coculture model
  28. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model
  29. Alternating Magnetic Field-Induced Hyperthermia Increases Iron Oxide Nanoparticle Cell Association/Uptake and Flux in Blood–Brain Barrier Models
  30. Introduction to the themed collection on nanoceria research
  31. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts
  32. Applying accelerator mass spectrometry for low-level detection of complex engineered nanoparticles in biological media
  33. In Vivo Processing of Ceria Nanoparticles inside Liver: Impact on Free-Radical Scavenging Activity and Oxidative Stress
  34. Nanoceria exposure, uptake, disposition, persistence, and resultant adverse effects
  35. Nanoceria biodistribution and retention in the rat after its intravenous administration are not greatly influenced by dosing schedule, dose, or particle shape
  36. Aluminum
  37. Rat hippocampal responses up to 90 days after a single nanoceria dose extends a hierarchical oxidative stress model for nanoparticle toxicity
  38. Binding, Transcytosis and Biodistribution of Anti-PECAM-1 Iron Oxide Nanoparticles for Brain-Targeted Delivery
  39. Persistent Hepatic Structural Alterations Following Nanoceria Vascular Infusion in the Rat
  40. Assessing nanoparticle risk poses prodigious challenges
  41. Metal-based nanoparticle interactions with the nervous system: the challenge of brain entry and the risk of retention in the organism
  42. Biodistribution and biopersistence of ceria engineered nanomaterials: size dependence
  43. Aluminum
  44. Block Copolymer Cross-Linked Nanoassemblies Improve Particle Stability and Biocompatibility of Superparamagnetic Iron Oxide Nanoparticles
  45. Rat brain pro-oxidant effects of peripherally administered 5nm ceria 30 days after exposure
  46. The neurotoxic potential of engineered nanomaterials
  47. Brain microvascular endothelial cell association and distribution of a 5 nm ceria engineered nanomaterial
  48. Influence of surface charge on lysozyme adsorption to ceria nanoparticles
  49. Alteration of hepatic structure and oxidative stress induced by intravenous nanoceria
  50. Distribution, Elimination, and Biopersistence to 90 Days of a Systemically Introduced 30 nm Ceria-Engineered Nanomaterial in Rats
  51. Ceria-engineered nanomaterial distribution in, and clearance from, blood: size matters
  52. Evaluation of 4-hydroxy-6-methyl-3-pyridinecarboxylic acid and 2,6-dimethyl-4-hydroxy-3-pyridinecarboxylic acid as chelating agents for iron and aluminium
  53. Engineered nanomaterials: exposures, hazards, and risk prevention
  54. Brain Distribution and Toxicological Evaluation of a Systemically Delivered Engineered Nanoscale Ceria
  55. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses
  56. Manganese Flux Across the Blood–Brain Barrier
  57. 1,6-Dimethyl-4-hydroxy-3-pyridinecarboxylic acid and 4-hydroxy-2-methyl-3-pyridinecarboxylic acid as new possible chelating agents for iron and aluminium
  58. Biodistribution and oxidative stress effects of a systemically-introduced commercial ceria engineered nanomaterial
  59. Aluminum bioavailability from tea infusion
  60. Manufactured Aluminum Oxide Nanoparticles Decrease Expression of Tight Junction Proteins in Brain Vasculature
  61. Aluminum bioavailability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese
  62. The influence of citrate, maltolate and fluoride on the gastrointestinal absorption of aluminum at a drinking water-relevant concentration: A 26Al and 14C study
  63. Interactions between SIRT1 and AP-1 reveal a mechanistic insight into the growth promoting properties of alumina (Al2O3) nanoparticles in mouse skin epithelial cells
  64. Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide
  65. Evaluation of 1-methyl-3,4-hydroxypyridinecarboxylic acids as possible bidentate chelating agents for iron(III): Metal–ligand solution chemistry
  66. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration
  67. Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water
  68. Methyl-Hydroxypyridinecarboxylic Acids as Possible Bidentate Chelating Agents for Aluminium(III): Synthesis and Metal–Ligand Solution Chemistry
  69. The Speciation of Metals in Mammals Influences Their Toxicokinetics and Toxicodynamics and Therefore Human Health Risk Assessment1
  70. The Chemical Species of Aluminum Influences Its Paracellular Flux across and Uptake into Caco-2 Cells, a Model of Gastrointestinal Absorption
  71. Manganese distribution across the blood–brain barrierIV. Evidence for brain influx through store-operated calcium channels
  72. 26Al-containing acidic and basic sodium aluminum phosphate preparation and use in studies of oral aluminum bioavailability from foods utilizing 26Al as an aluminum tracer
  73. Aluminium content of some foods and food products in the USA, with aluminium food additives
  74. Correlation of R2 with total iron concentration in the brains of rhesus monkeys
  75. Complexation of 3,4-hydroxypyridinecarboxylic acids with Iron(III)
  76. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice
  77. Manganese Distribution Across the Blood–Brain Barrier III The Divalent Metal Transporter-1 is not the Major Mechanism Mediating Brain Manganese Uptake
  78. Manganese Distribution Across the Blood–Brain Barrier
  79. Manganese Distribution Across the Blood–Brain Barrier
  80. Evaluation of 3,4-Hydroxypyridinecarboxylic Acids as Possible Bidentate Chelating Agents for Aluminium(III): Synthesis and Metal−Ligand Solution Chemistry
  81. Aluminum chelation principles and recent advances
  82. Aluminum citrate uptake by immortalized brain endothelial cells: implications for its blood–brain barrier transport
  83. Entry, Half-Life, and Desferrioxamine-Accelerated Clearance of Brain Aluminum after a Single 26Al Exposure
  84. Aluminum bioavailability from drinking water is very low and is not appreciably influenced by stomach contents or water hardness
  85. Glomerular lesions in male rabbits treated with aluminium lactate: with special reference to microaneurysm formation
  86. The Hexadentate Hydroxypyridinonate TREN‐(Me‐3,2‐HOPO) is a More Orally Active Iron Chelator Than Its Bidentate Analogue
  87. The distribution of aluminum into and out of the brain
  88. Postmortem elevation in extracellular glutamate in the rat hippocampus when brain temperature is maintained at physiological levels: implications for the use of human brain autopsy tissues
  89. Aluminum and phosphorus separation: application to preparation of target from brain tissue for 26Al determination by accelerator mass spectrometry
  90. Aluminum transport out of brain extracellular fluid is proton dependent and inhibited by mersalyl acid, suggesting mediation by the monocarboxylate transporter (MCT1)
  91. An Aluminum-Induced Increase in GFAP Is Attenuated by Some Chelators
  92. Aluminum citrate is transported from brain into blood via the monocar☐ylic acid transporter located at the blood-brain barrier
  93. Intraneuronal aluminum potentiates iron-induced oxidative stress in cultured rat hippocampal neurons
  94. Hippocampal Acetylcholine Increases During Eyeblink Conditioning in the Rabbit
  95. PREVENTION AND TREATMENT OF ALUMINUM TOXICITY INCLUDING CHELATION THERAPY: STATUS AND RESEARCH NEEDS
  96. Aluminum chelation by 3-hydroxypyridin-4-ones in the rat demonstrated by microdialysis
  97. The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ ol]-2-methyl-3-hydroxypyridin-4-one in the rat
  98. Aluminum Facilitation of Iron-Mediated Lipid Peroxidation Is Dependent on Substrate, pH, and Aluminum and Iron Concentrations
  99. HPLC Quantitation of a Very Hydrophilic 3-Hydroxypyridin-4-one Chelator Using a Simple Separation Procedure and the Baseline File Subtraction Method
  100. Delayed elevation of platelet activating factor in ischemic hippocampus
  101. Selective adherence of a sucralfate—tetracycline complex to gastric ulcers: Implications for the treatment ofHelicobacter pylori
  102. Evidence for energy-dependent transport of aluminum out of brain extracellular fluid
  103. A phase I trial of 5-day continuous infusion cisplatin and interferon ?
  104. Studies of aluminum neurobehavioral toxicity in the intact mammal
  105. Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy
  106. Application of electron energy loss spectroscopy and electron spectroscopic imaging to aluminum development in biological tissue
  107. Application of electron energy loss spectroscopy and electron spectroscopic imaging to aluminum development in biological tissue
  108. Application of electron energy loss spectroscopy and electron spectroscopic imaging to aluminum determination in biological tissue
  109. 4-trimethylammonium antipyrine: A quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysis
  110. Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis
  111. Dissimilar Aluminum and Gallium Permeation of the Blood-Brain Barrier Demonstrated by In Vivo Microdialysis
  112. Aluminum mobilization by desferrioxamine assessed by microdialysis of the blood, liver and brain☆☆☆
  113. Aluminum distribution into brain and liver of rats and rabbits following intravenous aluminum lactate or citrate: A microdialysis study*1, *2
  114. Renal accumulation and urinary excretion of cisplatin in diabetic rats
  115. Effect of Dietary Aluminum Sulfate on Calcium and Phosphorus Metabolism of Broiler Chicks
  116. Relationship of Dietary Aluminum, Phosphorus, and Calcium to Phosphorus and Calcium Metabolism and Growth Performance of Broiler Chicks
  117. Reduced intestinal calcium and dietary calcium intake, increased aluminum absorption, and tissue concentration in the rat
  118. The influence of dietary calcium reduction on aluminum absorption and kinetics in the rabbit
  119. Elevated aluminum persists in serum and tissues of rabbits after a six-hour infusion
  120. Aluminum produces age related behavioral toxicity in the rabbit
  121. Benefit Vs. Risk of Oral Aluminum Forms: Antacid and Phosphate Binding Vs. Absorption
  122. Aluminum and Alzheimer's Disease: Should We Worry?
  123. Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit
  124. Assessment of potential aluminum chelators in an octanol/aqueous system and in the aluminum-loaded rabbit
  125. Toxicity of aluminum exposure to the neonatal and immature rabbit*1, *2
  126. Toxicity of Aluminum Exposure to the Neonatal and Immature Rabbit
  127. Toxicity of gestational aluminum exposure to the maternal rabbit and offspring
  128. Aluminum bioavailability and disposition in adult and immature rabbits
  129. Toxicity of aluminum exposure during lactation to the maternal and suckling rabbit*1
  130. Persistent aluminum accumulation after prolonged systemic aluminum exposure
  131. A safe method to acid digest small samples of biological tissues for graphite furnace atomic absorption analysis of aluminum
  132. Evaluation of Factors Influencing the Patterns of Use of Drug and Poison Information Resources
  133. Acute toxicity of latex microspheres
  134. Effects of plant ingestion in rats determined by the conditioned taste aversion procedure
  135. The Impact of Video Technology on the Use of Drug Information Resources
  136. The Influence of Human and Data Retrieval Resources on the Patterns of Use of Drug Information
  137. Abuse and Pulmonary Complications of Injecting Pentazocine and Tripelennamine Tablets
  138. The influence of neuroleptics on amphetamine metabolism in the rat and guinea-pig*
  139. A comparison of four toxicology resources in respect to rates of retrieval and time required
  140. Amphetamine-type reinforcement by dopaminergic agonists in the rat
  141. Concurrent intracranial self-stimulation and amphetamine self-administration in rats
  142. Past, Present and Future of Drug Information Centers as Catalysts for the Utilization of Drug Therapy Information
  143. Drug Information Communication via Television
  144. Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats
  145. Extinction responding following amphetamine self-administration: Determination of reinforcement magnitude
  146. Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats
  147. Drug level of d- and l-amphetamine during intravenous self-administration
  148. Aluminum